Aprea Therapeutics, Inc. (APRE)

Latest Insider Confidence Score

2026Q1

52.5
Bullish

Company insider confidence (by quarter)

2019Q4 2026Q1

Largest shareholders

Insider Role (last 12 mo) Shares held Filed at
KDev Investments AB 10% Owner 1,992,586 Jul 7, 2020
Karolinska Development AB 10% Owner 1,992,586 Jul 7, 2020
KCIF Co-Investment Fund KB 10% Owner 1,992,586 Jul 7, 2020
Schwab Andrew J. Other 1,899,157 Oct 7, 2020
Diekman John D Other 1,899,157 Oct 7, 2020

Recent buy/sell transactions

Exec date Filing date Insider Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Jan 30, 2026 Feb 2, 2026 Gilad Oren CEO Buy 86.3 +28,100 8.09% ✗ $25K
Jan 30, 2026 Feb 2, 2026 Hamill John P. CFO Buy 90.0 +5,700 20.55% ✗ $5.1K
Dec 10, 2025 Dec 11, 2025 Duey Marc Director Buy 86.3 +21,459 9.12% ✗ $25K
Dec 10, 2025 Dec 11, 2025 Hamill John P. CFO Buy 90.0 +5,000 21.99% ✗ $5.8K
Dec 10, 2025 Dec 11, 2025 Gilad Oren CEO Neutral 52.5 - 0.00% ✗ -
Jun 5, 2025 Jun 9, 2025 Seizinger Bernd R. Director Neutral 77.5 +1,045 2.34% ✗ -
Jun 5, 2025 Jun 9, 2025 Peters Richard Director Neutral 90.0 +1,045 50.39% ✗ -
Jun 5, 2025 Jun 9, 2025 Pamukcu Rifat Director Neutral 85.0 +1,045 5.65% ✗ -
Jun 5, 2025 Jun 9, 2025 HENNEMAN JOHN B III Director Neutral 90.0 +1,045 11.38% ✗ -
Jun 5, 2025 Jun 9, 2025 Gruia Gabriela Director Neutral 90.0 +1,045 100.00% ✗ -
Jun 5, 2025 Jun 9, 2025 Grissinger Michael Director Neutral 90.0 +1,045 56.67% ✗ -
Jun 5, 2025 Jun 9, 2025 Duey Marc Director Neutral 60.0 +1,045 0.45% ✗ -
Jun 5, 2025 Jun 9, 2025 BIZZARI JEAN-PIERRE Director Neutral 90.0 +1,045 100.00% ✗ -
Apr 3, 2025 Apr 4, 2025 Gilad Oren CEO Buy 78.8 +5,500 1.61% ✗ $10.1K
Mar 27, 2025 Mar 31, 2025 Hamill John P. CFO Neutral 90.0 +3,365 17.37% ✗ -
Mar 27, 2025 Mar 31, 2025 Gilad Oren CEO Neutral 77.5 +6,725 2.01% ✗ -
Oct 18, 2024 Oct 25, 2024 Duey Marc Director Sell 26.3 -6,462 -2.68% ✗ $29.6K
Oct 23, 2024 Oct 24, 2024 Gilad Oren CEO Buy 55.0 +500 0.15% ✗ $2K
Oct 16, 2024 Oct 17, 2024 Duey Marc Director Buy 95.0 +30,000 14.24% ✗ $131.7K
Oct 15, 2024 Oct 16, 2024 Gilad Oren CEO Buy 55.0 +250 0.07% ✗ $725
Oct 14, 2024 Oct 16, 2024 Duey Marc Director Buy 55.0 +190 0.09% ✗ $490.2
Oct 11, 2024 Oct 16, 2024 Hamill John P. CFO Buy 60.0 +50 0.26% ✗ $123.2
Oct 11, 2024 Oct 15, 2024 Seizinger Bernd R. Director Buy 91.3 +10,000 28.79% ✗ $26.8K
Oct 10, 2024 Oct 15, 2024 Gilad Oren CEO Buy 60.0 +1,150 0.35% ✗ $3K
Oct 10, 2024 Oct 15, 2024 Hamill John P. CFO Buy 77.5 +450 2.38% ✗ $1.2K
Jun 20, 2024 Jun 21, 2024 Seizinger Bernd R. Director Neutral 82.5 +1,045 3.10% ✗ -
Jun 20, 2024 Jun 21, 2024 Pamukcu Rifat Director Neutral 85.0 +1,045 5.98% ✗ -
Jun 20, 2024 Jun 21, 2024 Peters Richard Director Neutral 90.0 +1,045 101.55% ✗ -
Jun 20, 2024 Jun 21, 2024 HENNEMAN JOHN B III Director Neutral 90.0 +1,045 12.84% ✗ -
Jun 20, 2024 Jun 21, 2024 Grissinger Michael Director Neutral 90.0 +1,045 130.79% ✗ -
Jun 20, 2024 Jun 21, 2024 Duey Marc Director Neutral 60.0 +1,045 0.50% ✗ -
May 1, 2024 May 2, 2024 Mirza Nadeem Q. Chief Medical Officer Neutral 90.0 +6,730 100.00% ✗ -
May 2, 2024 Mirza Nadeem Q. Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Mar 28, 2024 Mar 28, 2024 Hamill John P. CFO Neutral 90.0 +3,365 21.71% ✗ -
Mar 28, 2024 Mar 28, 2024 Gilad Oren CEO Neutral 77.5 +6,725 2.06% ✗ -
Mar 13, 2024 Mar 14, 2024 Hamill John P. CFO Buy 85.0 +1,010 6.97% ✗ $7.4K
Mar 13, 2024 Mar 14, 2024 Seizinger Bernd R. Director Buy 95.0 +6,860 25.57% ✗ $50K
Mar 13, 2024 Mar 14, 2024 HENNEMAN JOHN B III Director Buy 95.0 +6,860 536.36% ✗ $50K
Mar 13, 2024 Mar 14, 2024 Gilad Oren CEO Buy 68.8 +2,000 0.62% ✗ $14.6K
Aug 23, 2022 Aug 24, 2023 Pamukcu Rifat Director Neutral 90.0 +500 17.51% ✗ -
Aug 23, 2023 Aug 24, 2023 Grissinger Michael Director Neutral 90.0 +500 167.22% ✗ -
Aug 23, 2023 Aug 24, 2023 HENNEMAN JOHN B III Director Neutral 90.0 +500 64.18% ✗ -
Aug 23, 2023 Aug 24, 2023 Peters Richard Director Neutral 90.0 +500 94.52% ✗ -
Aug 23, 2022 Aug 24, 2023 Duey Marc Director Neutral 60.0 +500 0.24% ✗ -
Aug 23, 2023 Aug 24, 2023 Seizinger Bernd R. Director Neutral 77.5 +500 1.90% ✗ -
Aug 23, 2023 Aug 24, 2023 BIZZARI JEAN-PIERRE Director Neutral 52.5 - 0.00% ✗ -
Aug 24, 2023 BIZZARI JEAN-PIERRE Director Neutral 52.5 - 0.00% ✗ -
Jun 6, 2023 Jun 8, 2023 Seizinger Bernd R. Director Buy 91.3 +10,097 62.22% ✗ $37K
May 5, 2023 May 8, 2023 Gruia Gabriela Director Neutral 52.5 - 0.00% ✗ -
May 8, 2023 Gruia Gabriela Director Neutral 52.5 - 0.00% ✗ -
Aug 23, 2022 Mar 13, 2023 Gilad Oren CEO Neutral 77.5 +4,000 1.25% ✗ -
Feb 27, 2023 Feb 27, 2023 Hamill John P. CFO Neutral 85.0 +1,000 7.41% ✗ -
Jan 30, 2023 Jan 30, 2023 Hamill John P. CFO Neutral 90.0 +269,879 100.00% ✗ -
Jan 30, 2023 Hamill John P. CFO Neutral 52.5 - 0.00% ✗ -
Jul 28, 2022 Aug 1, 2022 Seizinger Bernd R. Director Neutral 77.5 +5,995 1.88% ✗ -
Jul 28, 2022 Aug 1, 2022 SCHADE CHRISTIAN S Director Neutral 90.0 +32,400 13.62% ✗ -
Jul 28, 2022 Aug 1, 2022 Peters Richard Director Neutral 90.0 +5,995 130.04% ✗ -
Jul 28, 2022 Aug 1, 2022 Pamukcu Rifat Director Neutral 90.0 +5,995 49.28% ✗ -
Jul 28, 2022 Aug 1, 2022 Korbel Gregory Alan COO Neutral 90.0 +24,300 113.22% ✗ -
Jul 28, 2022 Aug 1, 2022 HENNEMAN JOHN B III Director Neutral 90.0 +5,995 62.38% ✗ -
Jul 28, 2022 Aug 1, 2022 Grissinger Michael Director Neutral 90.0 +5,995 100.00% ✗ -
Jul 28, 2022 Aug 1, 2022 Gilad Oren CEO Neutral 90.0 +101,300 44.23% ✗ -
Jul 28, 2022 Aug 1, 2022 Duey Marc Director Neutral 82.5 +5,995 3.94% ✗ -
Jul 28, 2022 Aug 1, 2022 Coiante Scott M CFO Neutral 90.0 +60,800 72.15% ✗ -
Jun 3, 2022 Jun 7, 2022 SCHADE CHRISTIAN S CEO Sell 42.5 -65,770 -21.66% ✗ $52.9K
Jun 3, 2022 Jun 7, 2022 Coiante Scott M CFO Sell 46.3 -35,284 -29.51% ✗ $28.4K
Jun 3, 2022 Jun 7, 2022 Korbel Gregory Alan COO Sell 47.5 -8,390 -28.11% ✗ $6.8K
Jun 3, 2022 Jun 7, 2022 Attar Eyal C. SVP, Chief Medical Officer Sell 46.3 -32,667 -36.20% ✗ $26.3K
May 26, 2022 Grissinger Michael Director Neutral 52.5 - 0.00% ✗ -
May 26, 2022 Pamukcu Rifat Director Neutral 52.5 - 0.00% ✗ -
May 26, 2022 Gilad Oren President Neutral 52.5 - 0.00% ✗ -
May 26, 2022 Duey Marc Director Neutral 52.5 - 0.00% ✗ -
May 18, 2022 May 19, 2022 Seizinger Bernd R. Director Buy 91.3 +50,000 18.62% ✗ $35.5K
May 18, 2022 May 19, 2022 SCHADE CHRISTIAN S CEO Buy 91.3 +37,500 14.09% ✗ $24.1K
Mar 10, 2022 Mar 14, 2022 SCHADE CHRISTIAN S CEO Neutral 90.0 +100,100 60.30% ✗ -
Mar 10, 2022 Mar 14, 2022 Korbel Gregory Alan SVP, Chief Business Officer Sell 90.0 +14,011 88.45% ✗ $3.6K
Mar 10, 2022 Mar 14, 2022 Coiante Scott M CFO Neutral 90.0 +42,900 55.97% ✗ -
Mar 10, 2022 Mar 14, 2022 Attar Eyal C. SVP, Chief Medical Officer Neutral 90.0 +42,900 90.64% ✗ -
Mar 10, 2022 Mar 14, 2022 Abrahmsen Lars B. SVP, Chief Scientific Officer Neutral 90.0 +24,700 130.00% ✗ -
Feb 25, 2022 Mar 1, 2022 SCHADE CHRISTIAN S CEO Sell 46.3 -21,644 -11.53% ✗ $37.7K
Feb 25, 2022 Mar 1, 2022 Korbel Gregory Alan SVP, Chief Business Officer Sell 47.5 -1,326 -7.72% ✗ $2.3K
Feb 25, 2022 Mar 1, 2022 Coiante Scott M CFO Sell 46.3 -14,817 -16.20% ✗ $25.8K
Feb 28, 2022 Mar 1, 2022 Attar Eyal C. SVP, Chief Medical Officer Sell 10.0 -36,000 -43.20% ✓ $62.3K
Dec 1, 2021 Dec 3, 2021 Korbel Gregory Alan SVP, Chief Business Officer Sell 10.0 -27,500 -61.57% ✓ $108.9K
Nov 1, 2021 Nov 3, 2021 Korbel Gregory Alan SVP, Chief Business Officer Sell 10.0 -27,500 -61.57% ✓ $137.5K
Oct 1, 2021 Oct 5, 2021 Abrahmsen Lars B. SVP, Chief Scientific Officer Sell 10.0 -50,000 -72.46% ✓ $244.5K
Oct 1, 2021 Oct 5, 2021 Korbel Gregory Alan SVP, Chief Business Officer Sell 10.0 -27,500 -61.57% ✓ $134.5K
Sep 20, 2021 Sep 22, 2021 Korbel Gregory Alan SVP, Chief Business Officer Sell 10.0 -32,960 -48.98% ✓ $163.9K
Sep 20, 2021 Sep 22, 2021 Abrahmsen Lars B. SVP, Chief Scientific Officer Sell 10.0 -25,000 -56.82% ✓ $124.3K
Sep 16, 2021 Sep 20, 2021 Attar Eyal C. SVP, Chief Medical Officer Sell 20.0 -15,968 -16.08% ✓ $74.7K
Sep 10, 2021 Sep 14, 2021 Korbel Gregory Alan Chief Business Officer Sell 47.5 -1,724 -7.08% ✗ $7.9K
Aug 25, 2021 Aug 27, 2021 Korbel Gregory Alan Chief Business Officer Sell 47.5 -1,149 -4.51% ✗ $4.6K
Aug 25, 2021 Aug 27, 2021 Coiante Scott M CFO Sell 46.3 -7,534 -7.61% ✗ $30K
Aug 25, 2021 Aug 27, 2021 Attar Eyal C. SVP, Chief Medical Officer Sell 46.3 -9,032 -8.34% ✗ $35.9K
Jun 30, 2021 Jul 1, 2021 HENNEMAN JOHN B III Director Neutral 90.0 +4,610 92.20% ✗ -
Jun 30, 2021 Jul 1, 2021 Kelly Michael Aaron Director Neutral 90.0 +4,610 100.00% ✗ -
Jun 30, 2021 Jul 1, 2021 Peters Richard Director Neutral 90.0 +4,610 100.00% ✗ -
Jun 30, 2021 Jul 1, 2021 Seizinger Bernd R. Director Neutral 77.5 +4,610 1.75% ✗ -
Jun 30, 2021 Jul 1, 2021 Namouni Fouad Director Neutral 90.0 +4,610 100.00% ✗ -
Mar 10, 2021 Mar 11, 2021 Korbel Gregory Alan Chief Business Officer Neutral 90.0 +15,000 142.86% ✗ -